Treating diabetes by improving cardiac output

European Journal of Heart Failure

Volumn 13, Issue 2, 2011, Pages 133-134

  Van Der Horst, Iwan C C ^a   Tack, Cees J ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLYCOSYLATED HEMOGLOBIN; INSULIN; MESSENGER RNA; MITOCHONDRIAL PROTEIN; NEUROHORMONE; SOMATOMEDIN C; UNCOUPLING PROTEIN 3;

BODY FAT; CARDIAC RESYNCHRONIZATION THERAPY; DIABETES CONTROL; DIABETES MELLITUS; EDITORIAL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART ASSIST DEVICE; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; HORMONE ACTION; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; MUSCLE MASS; PHYSICAL ACTIVITY; PRIORITY JOURNAL;

BLOOD GLUCOSE; CARDIAC OUTPUT; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79551484927     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq235     Document Type: Editorial

References (13)

1. De Boer RA, Doehner W, Van der Horst IC, Anker SD, Babalis D, Roughton M, Coats AJ, Flather MD, Van Veldhuisen DJ, SENIORS Investigators. Influence of diabetes mellitus and hyperglycemia on prognosis in patients or 70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebi-volol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). Am J Cardiol 2010;106:78.e1-86.e1
2. Andersson C, Norgaard ML, Hansen PR, Fosbøl EL, Schmiegelow M, Weeke P, Olesen JB, Raunsø J, Jørgensen CH, Vaag A, Køber L, Torp-Pedersen C, Gislason GH. Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail 2010;12:1333-1338.
3. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009;52:752-764.
4. Gomes ME, Mulder A, Bellersen L, Verheugt FW, Smits P, Tack CJ. Alpha-receptor blockade improves muscle perfusion and glucose uptake in heart failure. Eur J Heart Fail 2010;12:1061-1066.
5. Uriel N, Colombo PC, Naka Y, Pak SW, Farr M, Cotarlan V, Albu J, Gallagher D, Ginsberg HN, Mancini D, Jorde U. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail 2011; 13:195-199.
6. Van der Horst IC, De Boer RA, Hillege HL, Boomsma F, Voors AA, Van Veldhuisen DJ. Neurohormonal profile of patients with heart failure and diabetes. Neth Heart J 2010;18:190-196.
7. Qanud K, Mamdani M, Pepe M, Khairallah RJ, Gravel J, Lei B, Gupte SA, Sharov VG, Sabbah HN, Stanley WC, Recchia FA. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure. Am J Physiol Heart Circ Physiol 2008;295:H2098-H2105.
8. Doenst T, Bugger H, Leippert S, Barleon B, Marme D, Beyersdorf F. Differential gene expression in response to ventricular unloading in rat and human myocardium. Thorac Cardiovasc Surg 2006;54:381-387.
9. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, Van Veldhuisen DJ. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010;12:1143-1153.
10. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resyn-chronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 2007;13:769-773.
11. Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, Shipley GL, Moravec CS, Davies PJ, Frazier OH, Taegtmeyer H. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 2002;97:203-209.
12. Barton PJ, Felkin LE, Birks EJ, Cullen ME, Banner NR, Grindle S, Hall JL, Miller LW, Yacoub MH. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation 2005;112(Suppl. 9):I46-I50.
13. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH, HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361: 2241-2251.